NCE Discovery

poziotinib (pan-HER)

• Most effective pan-HER inhibitor
• Effective for EGFR mutant and HER2 positive/mutant driven solid tumors
• Potent inhibition of EGFR and HER2 exon 20 mutations

belvarafenib (pan-RAF)

• Potent pan-RAF inhibitor
• Effective anti-tumor activities in RAF and RAS mutant driven cancers

HM43239

• Potent inhibitor of FMS-like tyrosine kinase 3 (FLT3) and FLT3 mutants including tyrosine kinase domain.
• Effective therapy for the FLT3 mutants driven cancers, such as AML

HM71224

• Effective Bruton’s tyrosine kinase (BTK) inhibitor
• Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLCγ